 |
| Boston Scientific's Promus Premier coronary stent--Courtesy of Boston Scientific |
Boston Scientific ($BSX) rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan. The everolimus-releasing platinum-chromium stent is part of the company's sales and marketing strategy as it looks for a blockbuster product to kick-start its revenue growth. "Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific's overall growth strategy in the DES [drug eluting stent] market," said interventional cardiology president Kevin Ballinger in a statement. More